Larry W Moreland

List of Publications by Citations

Source: https://exaly.com/author-pdf/9327888/larry-w-moreland-publications-by-citations.pdf

Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31,056 69 175 234 h-index g-index citations papers 6.12 35,850 253 7.2 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
234	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2569-81		4825
233	2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1580-8	2.4	2158
232	A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2000 , 343, 1586-93	59.2	1551
231	Genetics of rheumatoid arthritis contributes to biology and drug discovery. <i>Nature</i> , 2014 , 506, 376-81	50.4	1426
230	Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. <i>Arthritis and Rheumatism</i> , 2003 , 48, 35-45		1398
229	Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. <i>New England Journal of Medicine</i> , 1997 , 337, 141-7	59.2	1375
228	2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012 , 64, 625-39	4.7	1199
227	American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 762-	84	1118
226	Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. <i>Annals of Internal Medicine</i> , 1999 , 130, 478-86	8	959
225	Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. <i>New England Journal of Medicine</i> , 2006 , 354, 795-808	59.2	901
224	Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. <i>New England Journal of Medicine</i> , 2003 , 349, 1907-15	59.2	822
223	Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1443-50		570
222	Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. <i>Annals of Internal Medicine</i> , 2006 , 144, 865-76	8	524
221	Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2002 , 46, 614-24		481
220	Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1412-9		395
219	Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2263-71		370
218	Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. <i>Nature Immunology</i> , 2019 , 20, 928-942	19.1	369

(2008-2009)

217	subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled		334
216	Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1470-9		310
215	REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. <i>Nature Genetics</i> , 2009 , 41, 820-3	36.3	272
214	A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2824-35		271
213	High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. <i>Arthritis and Rheumatism</i> , 1999 , 42, 1194-203	3	261
212	Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. <i>Clinical Therapeutics</i> , 2003 , 25, 1700-21	3.5	245
211	Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1977-83		244
210	Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1984-92		227
209	Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. <i>Arthritis and Rheumatism</i> , 2000 , 43, 2445-54		221
208	Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2015-25		211
207	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2582	2-91	182
206	Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. <i>Annals of Internal Medicine</i> , 2000 , 132, 871-9	3	175
205	Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1460-9		169
204	Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2983-9		159
203	A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis and Rheumatology, 2017 , 69, 837-845).5	155
202	The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. <i>Arthritis and Rheumatism</i> , 2004 , 50, 2750-6		140
201	Abatacept. <i>Nature Reviews Drug Discovery</i> , 2006 , 5, 185-6	ó4.1	138
200	Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. <i>Arthritis and Rheumatism</i> , 2008 , 58, 953-63		137

199	Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2882-91		129
198	Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. <i>PLoS Genetics</i> , 2013 , 9, e1003394	6	127
197	Phenome-wide association study (PheWAS) for detection of pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network. <i>PLoS Genetics</i> , 2013 , 9, e1003087	6	126
196	Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1993 , 36, 307-18		122
195	Biologic agents for treating rheumatoid arthritis. Concepts and progress. <i>Arthritis and Rheumatism</i> , 1997 , 40, 397-409		121
194	Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004 , 50, 2858-68		115
193	Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. ORTHOVISC Study Group. <i>Clinical Orthopaedics and Related Research</i> , 2001 , 130-43	2.2	109
192	Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1102-11		108
191	Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1430-8		107
190	Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts. <i>Arthritis and Rheumatism</i> , 1994 , 37, 834-8		106
189	Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. <i>Journal of Rheumatology</i> , 2005 , 32, 832-40	4.1	101
188	Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. <i>Journal of Rheumatology</i> , 2009 , 36, 736-42	4.1	100
187	A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. <i>American Journal of Human Genetics</i> , 2015 , 96, 565-80	11	96
186	Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2020-8		96
185	Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1581-8		96
184	Inflammatory central nervous system involvement in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1989 , 18, 258-66	5.3	96
183	Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. <i>Journal of Rheumatology</i> , 2013 , 40, 787-97	4.1	93
182	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1054-1066	9.5	85

(2008-2008)

181	A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1810-22		85
180	Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1996 , 39, 257-65		85
179	Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005 , 32, 1232-42	4.1	85
178	The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. <i>Arthritis and Rheumatism</i> , 2001 , 44, 653-61		84
177	Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999 , 42, 2372-80		84
176	A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 846-853	9.5	82
175	Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2010 , 37, 275-81	4.1	82
174	Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. <i>Clinical Therapeutics</i> , 2000 , 22, 128-39	3.5	82
173	Sedentary behavior and mortality in older women: the Women@ Health Initiative. <i>American Journal of Preventive Medicine</i> , 2014 , 46, 122-35	6.1	81
172	. Arthritis Research, 2000 , 1, S47		-0
-,-	Aramas Research, 2000 , 1, 547		78
171	Validation of American College of Rheumatology classification criteria for knee osteoarthritis using arthroscopically defined cartilage damage scores. Seminars in Arthritis and Rheumatism, 2005, 35, 197-20	o∮·3	78
	Validation of American College of Rheumatology classification criteria for knee osteoarthritis using	o₹·³	
171	Validation of American College of Rheumatology classification criteria for knee osteoarthritis using arthroscopically defined cartilage damage scores. <i>Seminars in Arthritis and Rheumatism</i> , 2005 , 35, 197-20. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1849-61. Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic	0 ⁵ i ⁻³	77
171 170	Validation of American College of Rheumatology classification criteria for knee osteoarthritis using arthroscopically defined cartilage damage scores. <i>Seminars in Arthritis and Rheumatism</i> , 2005 , 35, 197-20. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1849-61. Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic		77 74
171 170 169	Validation of American College of Rheumatology classification criteria for knee osteoarthritis using arthroscopically defined cartilage damage scores. <i>Seminars in Arthritis and Rheumatism</i> , 2005 , 35, 197-20. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1849-61. Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 475-82. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate.	5.3	77 74 73
171 170 169 168	Validation of American College of Rheumatology classification criteria for knee osteoarthritis using arthroscopically defined cartilage damage scores. <i>Seminars in Arthritis and Rheumatism</i> , 2005 , 35, 197-20 Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1849-61 Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 475-82 Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. <i>American Journal of Medicine</i> , 1991 , 90, 295-298 Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. <i>Clinical</i>	5.3 2.4 11.6	77 74 73 70
171 170 169 168	Validation of American College of Rheumatology classification criteria for knee osteoarthritis using arthroscopically defined cartilage damage scores. Seminars in Arthritis and Rheumatism, 2005, 35, 197-20. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis and Rheumatism, 2010, 62, 1849-61. Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. Seminars in Arthritis and Rheumatism, 2016, 45, 475-82. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. American Journal of Medicine, 1991, 90, 295-298. Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. Clinical Infectious Diseases, 2009, 49, 924-7.	5.3 2.4 11.6	77 74 73 70 69

163	Reactive arthritis in patients attending an urban sexually transmitted diseases clinic. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1172-7		68
162	Ultrasound detection of bone erosions in rheumatoid arthritis: a comparison to routine radiographs of the hands and feet. <i>Skeletal Radiology</i> , 2004 , 33, 80-4	2.7	66
161	Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. <i>Arthritis and Rheumatism</i> , 1999 , 42, 357-65		66
160	T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides. <i>Arthritis and Rheumatism</i> , 1998 , 41, 1919-29		65
159	Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. <i>Drug Design, Development and Therapy,</i> 2010 , 4, 263-78	4.4	64
158	Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients. <i>Seminars in Arthritis and Rheumatism</i> , 1989 , 19, 31-44	5.3	62
157	Methods for high-dimensional analysis of cells dissociated from cryopreserved synovial tissue. <i>Arthritis Research and Therapy</i> , 2018 , 20, 139	5.7	60
156	Cutaneous polyarteritis nodosa. <i>American Journal of Medicine</i> , 1990 , 88, 426-30	2.4	59
155	Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. Journal of Rheumatology, 2006 , 33, 2162-6	4.1	57
154	Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1177-86		56
153	Ludwig@ Angina. Archives of Internal Medicine, 1988, 148, 461		56
152	Inter-observer reliability of the arthroscopic quantification of chondropathy of the knee. <i>Osteoarthritis and Cartilage</i> , 1998 , 6, 160-6	6.2	55
151	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. <i>Nature Communications</i> , 2016 , 7, 12460	17.4	54
150	Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. <i>Arthritis and Rheumatism</i> , 2013 , 65, 198	35-94	53
149	Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. <i>Journal of Rheumatology</i> , 2003 , 30, 691-6	4.1	53
148	Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 1998 , 24, 579-91	2.4	52
147	Cardiac Involvement in Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2015 , 42, 1209-12	4.1	50
146	Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. <i>Pharmacoeconomics</i> , 2004 , 22, 39-53	4.4	49

Acute febrile neutrophilic dermatosis (Sweet syndrome): a review of the literature with emphasis on musculoskeletal manifestations. <i>Seminars in Arthritis and Rheumatism</i> , 1988 , 17, 143-53	5.3	49	
Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. <i>Seminars in Arthritis and Rheumatism</i> , 2009 , 39, 132-43	5.3	48	
Most common single-nucleotide polymorphisms associated with rheumatoid arthritis in persons of European ancestry confer risk of rheumatoid arthritis in African Americans. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3547-53		47	
Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1051-66		47	
Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. <i>Journal of Rheumatology</i> , 2004 , 31, 1532-7	4.1	45	
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017 , 100, 64-74	11	43	
Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women@ Health Initiative. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2311-22	9.5	43	
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. <i>Seminars in Arthritis and Rheumatism</i> , 2004 , 33, 249-63	5.3	43	
Associations of cigarette smoking with rheumatoid arthritis in African Americans. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3560-8		42	
Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006 , 55, 287-93		41	
Upcoming biologic agents for the treatment of rheumatic diseases. <i>Current Opinion in Rheumatology</i> , 2003 , 15, 226-36	5.3	40	
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 878-891	9.5	38	
Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. <i>Arthritis Research</i> , 2001 , 3, 247-52		38	
Spinal stenosis: a comprehensive review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 1989 , 19, 127-49	5.3	37	
Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study. <i>Arthritis Care and Research</i> , 2018 , 70, 197-204	4.7	36	
TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. <i>Expert Opinion on Pharmacotherapy</i> , 2001 , 2, 75-84	4	36	
Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1991 , 60, 412-8		36	
Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker. <i>Arthritis Research and Therapy</i> , 2016 , 18, 108	5.7	36	
	On musculoskeletal manifestations. Seminars in Arthritis and Rheumatism, 1988, 17, 143-53 Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. Seminars in Arthritis and Rheumatism, 2009, 39, 132-43 Most common single-nucleotide polymorphisms associated with rheumatoid arthritis in persons of European ancestry confer risk of rheumatoid arthritis in African Americans. Arthritis and Rheumatism, 2010, 62, 3547-53 Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis and Rheumatism, 2007, 56, 1051-66 Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. Journal of Rheumatology, 2004, 31, 1532-7 A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74 Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women@ Health Initiative. Arthritis and Rheumatology, 2015, 67, 2311-22 High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Seminars in Arthritis and Rheumatism, 2004, 33, 249-63 Associations of cigarette smoking with rheumatoid arthritis in African Americans. Arthritis and Rheumatism, 2010, 62, 3560-8 Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis and Rheumatism, 2006, 55, 287-93 Upcoming biologic agents for the treatment of rheumatic diseases. Current Opinion in Rheumatism, 2006, 55, 287-93 Upcoming biologic agents for the treatment of rheumatic diseases. Current Opinion in Rheumatism, 11 (rhill-11) in the treatment of subjects with active rheumatoid Arthritis. Arthritis and Rheumatology, 2013, 71, 878-891 Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhill-11) in the treatment of subjects with active rheumatoid arthri	Systemic nonarticular manifestations. Seminars in Arthritis and Rheumatism, 1988, 17, 143-53 Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. Seminars in Arthritis and Rheumatism, 2009, 39, 132-43 Most common single-nucleotide polymorphisms associated with rheumatoid arthritis in persons of European ancestry confer risk of rheumatoid arthritis in African Americans. Arthritis and Rheumatism, 2010, 62, 3547-53 Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis and Rheumatism, 2007, 56, 1051-66 Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. Journal of Rheumatoiogy, 2004, 31, 1532-7 A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74 Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women@ Health Initiative. Arthritis and Rheumatology, 2015, 67, 2311-22 High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Seminars in Arthritis and Rheumatism, 2004, 33, 249-63 Associations of cigarette smoking with rheumatoid arthritis in African Americans. Arthritis and Rheumatism, 2010, 62, 3560-8 Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis and Rheumatism, 2006, 55, 287-93 Upcoming biologic agents for the treatment of rheumatic diseases. Current Opinion in Rheumatology, 2003, 15, 226-36 Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. Arthritis Research, 2001, 3, 247-52 Spinal stenosis: a comprehensive review of the literature. Seminars in Arthritis and Rheumatism, 1989, 19, 127-49 Association Between Pain Sensitization and Disease Activit	Systemic nonarticular manifestations. Seminars in Arthritis and Rheumatism, 1988, 17, 143-53 53 49 Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. Seminars in Arthritis and Rheumatism, 2009, 39, 132-43 Most common single-nucleotide polymorphisms associated with rheumatoid arthritis in persons of European ancestry confer risk of rheumatoid arthritis in African Americans. Arthritis and Rheumatism, 2010, 62, 3547-53 Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis and Rheumatism, 2010, 56, 1051-66 Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. Journal of Rheumatology, 2004, 31, 1532-7 A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis, American Journal of Human Genetics, 2017, 100, 64-74 Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the WomenQ Health Initiative. Arthritis and Rheumatology, 2015, 67, 2311-22 High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Seminars in Arthritis and Rheumatism, 2006, 33, 249-63 Associations of cigarette smoking with rheumatoid arthritis in African Americans. Arthritis and Rheumatism, 2010, 62, 3560-8 Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis and Rheumatism, 2006, 55, 287-93 Upcoming biologic agents for the treatment of rheumatic diseases. Current Opinion in Rheumatology, 2003, 15, 226-36 195 38 Associations of cigarette smoking with Methotrevate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. Arthritis and Rheumatology, 2019, 71, 878-891 Sampae-Vill randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhll11) in the treatment of subjects with act

127	Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2017 , 69, 46-57	9.5	34
126	Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: the impact of ethnic-specific normative data. <i>Journal of the National Medical Association</i> , 2005 , 97, 1155-60	2.3	34
125	Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. <i>American Journal of Medicine</i> , 1991 , 90, 295-298	2.4	33
124	Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2005 , 5, 1245-54	5.4	32
123	Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial. <i>Arthritis and Rheumatology</i> , 2016 , 68, 577-	-8&	32
122	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020 , 72, 1615-1624	4.7	32
121	The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis. <i>Journal of Medicinal Food</i> , 2009 , 12, 1143-8	2.8	29
120	Perioperative use of methotrexate in patients with rheumatoid arthritis undergoing orthopedic surgery. <i>Rheumatic Disease Clinics of North America</i> , 1997 , 23, 981-93	2.4	29
119	Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in African Americans with early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006 , 54, 3057-9		29
118	Persistence of Disease-Associated Anti-Citrullinated Protein Antibody-Expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1176-1186	9.5	27
117	Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2013 , 40, 1812-22	4.1	27
116	Domains of health-related quality of life important to patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2003 , 49, 819-25		27
115	A clinical and economic review of disease-modifying antirheumatic drugs. <i>Pharmacoeconomics</i> , 2001 , 19, 715-28	4.4	27
114	Radiographic severity of rheumatoid arthritis in African Americans: results from a multicenter observational study. <i>Arthritis Care and Research</i> , 2010 , 62, 624-31	4.7	26
113	Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. <i>Drug Safety</i> , 2003 , 26, 23-32	5.1	26
112	Increased pretreatment serum IFN-加atio predicts non-response to tumour necrosis factor 日 inhibition in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1757-62	2.4	25
111	Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2219-26		25
110	Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. <i>Drugs and Aging</i> , 2006 , 23, 167-78	4.7	25

(2014-2012)

109	Impact of interactions of cigarette smoking with NAT2 polymorphisms on rheumatoid arthritis risk in African Americans. <i>Arthritis and Rheumatism</i> , 2012 , 64, 655-64		24	
108	Integration of sequence data from a Consanguineous family with genetic data from an outbred population identifies PLB1 as a candidate rheumatoid arthritis risk gene. <i>PLoS ONE</i> , 2014 , 9, e87645	3.7	24	
107	A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2864-75		24	
106	Specific cyclooxygenase 2 inhibitors: a new choice of nonsteroidal anti-inflammatory drug therapy. <i>Arthritis and Rheumatism</i> , 1999 , 12, 351-62		24	
105	Intraarticular corticosteroid injections: should we rest the joints?. Arthritis and Rheumatism, 1989, 2, 70)-4	24	
104	Update on Cardiovascular Disease Risk in Patients with Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2018 , 44, 475-487	2.4	22	
103	Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy. <i>Arthritis Care and Research</i> , 2015 , 67, 929-39	4.7	22	
102	Calcium and vitamin D supplementation and incident rheumatoid arthritis: the Women@ Health Initiative Calcium plus Vitamin D trial. <i>Rheumatology International</i> , 2012 , 32, 3823-30	3.6	22	
101	High-resolution ultrasound for the study of target joints in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1969-70; author reply 1970-1		22	
100	Transforming growth factor beta within fibrotic scleroderma lungs. <i>American Journal of Medicine</i> , 1992 , 93, 628-36	2.4	22	
99	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019 , 58, 2203-2211	3.9	21	
98	Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 1751-1757	4.7	21	
97	Arterial lesions in giant cell arteritis: A longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 707-713	5.3	21	
96	Determinants of mortality among postmenopausal women in the women@health initiative who report rheumatoid arthritis. <i>Arthritis and Rheumatology</i> , 2014 , 66, 497-507	9.5	21	
95	Immunohistologic demonstration of type II collagen in synovial fluid phagocytes of osteoarthritis and rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 1989 , 32, 1458-64		21	
94	Evaluation of damage in giant cell arteritis. <i>Rheumatology</i> , 2018 , 57, 322-328	3.9	20	
93	Family Planning Counseling for Women With Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2018 , 70, 169-174	4.7	20	
92	Complementary and alternative medicine use in African Americans with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2014 , 66, 180-9	4.7	20	

91	Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. <i>Nature Genetics</i> , 2013 , 45, 468-9	36.3	20
90	Unmet needs in rheumatoid arthritis. Arthritis Research and Therapy, 2005, 7 Suppl 3, S2-8	5.7	20
89	Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drug. <i>Arthritis and Rheumatism</i> , 2004 , 51, 933-40		20
88	Genetic variants of STAT4 associated with rheumatoid arthritis in persons of Asian and European ancestry do not replicate in African Americans. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 625-6	2.4	19
87	Rheumatoid arthritis: developing pharmacological therapies. <i>Expert Opinion on Investigational Drugs</i> , 2004 , 13, 1007-18	5.9	19
86	Growth factors, extracellular matrix, and oncogenes in scleroderma. <i>Arthritis and Rheumatism</i> , 1992 , 35, 304-10		19
85	Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial. <i>Journal of Rheumatology</i> , 2013 , 40, 572-8	4.1	18
84	Association of IL4R single-nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2010 , 12, R75	5.7	17
83	Contraception Use Among Reproductive-Age Women With Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2019 , 71, 1132-1140	4.7	16
82	Improvement in Herpes Zoster Vaccination in Patients with Rheumatoid Arthritis: A Quality Improvement Project. <i>Journal of Rheumatology</i> , 2017 , 44, 11-17	4.1	16
81	Effects of nonsteroidal antiinflammatory drugs on bone loss in chronic inflammatory disease. <i>Annals of the New York Academy of Sciences</i> , 1993 , 696, 292-302	6.5	16
80	Practice pattern variation among internal medicine specialists in the prevention of glucocorticoid-induced osteoporosis. <i>Journal of Clinical Rheumatology</i> , 2000 , 6, 117-22	1.1	16
79	Certolizumab pegol: a new biologic targeting rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2010 , 6, 855-66	5.1	15
78	Potential biologic agents for treating rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2001 , 27, 445-91	2.4	15
77	New therapeutic approaches to the management of rheumatoid arthritis. <i>BioDrugs</i> , 2001 , 15, 379-93	7.9	15
76	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. <i>Journal of Medical Internet Research</i> , 2017 , 19, e50	7.6	15
75	Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2. <i>Arthritis and Rheumatology</i> , 2021 , 73, 512-519	9.5	15
74	Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug. Arthritis Care and Research 2019, 71, 521-529	4.7	14

73	Cardiovascular Disease Risk in Patients with Rheumatic Diseases. <i>Clinics in Geriatric Medicine</i> , 2017 , 33, 105-117	3.8	14
72	Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012 , 64, 1804-10	4.7	14
71	Biologic therapies on the horizon for rheumatoid arthritis. <i>Journal of Clinical Rheumatology</i> , 2004 , 10, S32-9	1.1	14
70	Analysis of CXCR5Th17 cells in relation to disease activity and TNF inhibitor therapy in Rheumatoid Arthritis. <i>Scientific Reports</i> , 2016 , 6, 39474	4.9	14
69	Febuxostattreatment for hyperuricemia and gout?. New England Journal of Medicine, 2005, 353, 2505-	759.2	13
68	The use of analgesics in the management of pain in rheumatic diseases. <i>Rheumatic Disease Clinics of North America</i> , 1999 , 25, 153-91, vii	2.4	12
67	Derivation of an angiographically based classification system in Takayasu@arteritis: an observational study from India and North America. <i>Rheumatology</i> , 2020 , 59, 1118-1127	3.9	12
66	14-3-3z sequesters cytosolic T-bet, upregulating IL-13 levels in T2 and CD8 lymphocytes from patients with scleroderma. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 142, 109-119.e6	11.5	11
65	Induction therapy with combination TNF inhibitor and methotrexate in early rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2014 , 16, 417	4.9	10
64	T-cell receptor peptide vaccination in the treatment of rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 1998 , 24, 641-50	2.4	10
63	Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. <i>Clinical Immunology</i> , 2007 , 123, 235-43	9	10
62	New approaches to the therapy of autoimmune diseases: rheumatoid arthritis as a paradigm. <i>American Journal of the Medical Sciences</i> , 1993 , 305, 40-51	2.2	10
61	B cells in rheumatoid arthritis synovial tissues encode focused antibody repertoires that include antibodies that stimulate macrophage TNF-[production. <i>Clinical Immunology</i> , 2020 , 212, 108360	9	9
60	Socioeconomic factors and self-reported health outcomes in African Americans with rheumatoid arthritis from the Southeastern United States: the contribution of childhood socioeconomic status. BMC Musculoskeletal Disorders, 2016 , 17, 10	2.8	9
59	Rheumatoid arthritis in the Women@ Health Initiative: methods and baseline evaluation. <i>American Journal of Epidemiology</i> , 2014 , 179, 917-26	3.8	9
58	An African ancestry-specific allele of CTLA4 confers protection against rheumatoid arthritis in African Americans. <i>PLoS Genetics</i> , 2009 , 5, e1000424	6	9
57	Clinical and pharmacological experience with etanercept. <i>Expert Opinion on Investigational Drugs</i> , 1999 , 8, 1443-51	5.9	9
56	The use of methotrexate perioperatively in patients with rheumatoid arthritis undergoing major joint replacement surgery: will we ever have consensus about its use?. <i>Journal of Clinical Rheumatology</i> , 1996 , 2, 6-8	1.1	9

55	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , 2020 , 47, 1001-1010	4.1	9
54	Socioeconomic disparities in the health of african americans with rheumatoid arthritis from the southeastern United States. <i>Arthritis Care and Research</i> , 2014 , 66, 1808-17	4.7	8
53	Cytokines as targets for anti-inflammatory agents. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1182, 88-96	6.5	8
52	Associations of alcohol use with radiographic disease progression in African Americans with recent-onset rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2013 , 40, 1498-504	4.1	7
51	Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions. <i>Pharmacoepidemiology and Drug Safety</i> , 2006 , 15, 11-8	2.6	7
50	Rheumatoid arthritis: developing pharmacological therapies. <i>Expert Opinion on Investigational Drugs</i> , 2002 , 11, 927-35	5.9	7
49	Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity. <i>PLoS ONE</i> , 2021 , 16, e0244187	3.7	7
48	Predictive value of autoantibody testing for validating self-reported diagnoses of rheumatoid arthritis in the Women@ Health Initiative. <i>American Journal of Epidemiology</i> , 2013 , 177, 887-93	3.8	6
47	Health status response of rheumatoid arthritis to treatment with DAB486IL-2. <i>Arthritis and Rheumatism</i> , 1996 , 9, 112-9		6
46	Synovial Biopsy of the Knee Joint under Direct Visualization by Needle Arthroscopy. <i>Journal of Clinical Rheumatology</i> , 1995 , 1, 103-9	1.1	6
45	Rheumatoid arthritis patients and clinical drug trials. A case-control study. <i>Arthritis and Rheumatism</i> , 1991 , 4, 22-6		6
44	Patterns of clinical presentation in Takayasu@arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 576-581	5.3	6
43	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. <i>PLoS ONE</i> , 2018 , 13, e0205768	3.7	5
42	Adalimumab in rheumatoid arthritis. Current Rheumatology Reports, 2004, 6, 333-4	4.9	5
41	Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 785-6	2.4	4
40	Adalimumab in rheumatoid arthritis. Current Rheumatology Reports, 2004, 6, 333-334	4.9	4
39	Improving Pneumococcal Vaccination Rates in Rheumatology Patients by Using Best Practice Alerts in the Electronic Health Records. <i>Journal of Rheumatology</i> , 2021 , 48, 1472-1479	4.1	4
38	Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021 , 3, 404-412	3.5	4

(2002-2019)

37	Pain and Catastrophizing in Patients With Rheumatoid Arthritis: An Observational Cohort Study. Journal of Clinical Rheumatology, 2019 , 25, 232-236	1.1	4
36	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019 , 46, 928-934	4.1	3
35	Long-Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis. <i>Arthritis Care and Research</i> , 2021 , 73, 1372-1378	4.7	3
34	How do we best measure the clinical benefit of a structure-modifying osteoarthritis drug?. <i>Osteoarthritis and Cartilage</i> , 2004 , 12 Suppl A, S61-2	6.2	3
33	Infliximab in rheumatoid arthritis. Current Rheumatology Reports, 2004, 6, 334-5	4.9	3
32	Recent advances in anti-tumour necrosis factor (TNF) therapy in rheumatoid arthritis: focus on the soluble TNF receptor p75 fusion protein, etanercept. <i>BioDrugs</i> , 1999 , 11, 201-10	7.9	3
31	Inflammatory joint diseases and atherosclerosis: time to look beyond the <code>@pid</code> paradoxQ <i>Current Opinion in Lipidology</i> , 2019 , 30, 342-349	4.4	3
30	Human Leukocyte Antigen Shared Epitope and Inflammation, Cardiovascular Disease, Cancer, and Mortality Among Postmenopausal Women in the Women@ Health Initiative Rheumatoid Arthritis Study. <i>American Journal of Epidemiology</i> , 2017 , 186, 245-254	3.8	2
29	JAK inhibition in rheumatoid arthritis. Current Rheumatology Reports, 2011, 13, 379-80	4.9	2
28	Vaccination against rheumatoid arthritis: concepts and progress. <i>BioDrugs</i> , 1997 , 8, 87-95	7.9	2
27	Predicting outcomes in early rheumatoid arthritis. Current Rheumatology Reports, 2002, 4, 193-4	4.9	2
26	The treatment of rheumatoid arthritis: a review of recent clinical trials. <i>Current Rheumatology Reports</i> , 1999 , 1, 135-8	4.9	2
25	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 103, 98-101	2.2	2
24	Post-GWAS functional studies reveal an RA-associated CD40-induced NF-kB signal transduction and transcriptional regulation network targeted by class II HDAC inhibitors. <i>Human Molecular Genetics</i> , 2021 , 30, 823-835	5.6	2
23	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 129, 114-118	2.2	2
22	Certolizumab pegol in active rheumatoid arthritis. Current Rheumatology Reports, 2009, 11, 311-2	4.9	1
21	Tocilizumab versus methotrexate in moderate to severe rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2009 , 11, 313-4	4.9	1
20	Genetic influences on rheumatoid arthritis in African Americans. <i>Immunologic Research</i> , 2002 , 26, 15-26	4.3	1

19	Improved methotrexate patient information. Arthritis and Rheumatism, 1995, 38, 874-5		1
18	Comment on the article by Furst et al. Arthritis and Rheumatism, 1989, 32, 1631-2		1
17	Transcriptional Regulation of Expression by 4 Ribosomal Proteins via a Functional SNP on a Disease-Associated Locus. <i>Genes</i> , 2020 , 11,	4.2	1
16	A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3B Methodology Applied to Two Active Comparator Trials. <i>Arthritis Care and Research</i> , 2019 , 71, 319-322	4.7	1
15	Etanercept and methotrexate combination in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2004 , 6, 333	4.9	1
14	Adalimumab Immunogenicity Is Negatively Correlated with Anti-Hinge Antibody Levels in Patients with Rheumatoid Arthritis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020 , 375, 488-497	4.7	O
13	A review of biosimilars for rheumatoid arthritis Current Opinion in Pharmacology, 2022, 64, 102234	5.1	O
12	Identifying Vulnerable Plaque in Rheumatoid Arthritis Using Novel Microbubble Contrast-Enhanced Carotid Ultrasonography and Serum Biomarkers. <i>Journal of Diagnostic Medical Sonography</i> , 2020 , 36, 300-310	0.4	
11	Reply. Arthritis and Rheumatology, 2016 , 68, 555-6	9.5	
10	Reply: The effect of triple therapy versus etanercept plus methotrexate in rheumatoid arthritis: comment on the article by Moreland et al. <i>Arthritis and Rheumatism</i> , 2013 , 65, 539-40		
9	Inhibition of spleen tyrosine kinase for rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2011 , 13, 377-8	4.9	
8	Cost-effectiveness of biologics compared with disease-modifying antirheumatic drugs in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2011 , 13, 381-2	4.9	
7	Methotrexate versus combination methotrexate and etanercept for rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2009 , 11, 309-10	4.9	
6	Efficacy and safety of rituximab in rheumatoid arthritis patients refractory to methotrexate. <i>Current Rheumatology Reports</i> , 2006 , 8, 368-368	4.9	
5	Humanized anti-interleukin-6 receptor antibody. Current Rheumatology Reports, 2005, 7, 381-381	4.9	
4	Viral arthritis in humans. <i>Current Opinion in Rheumatology</i> , 1989 , 1, 185-93	5.3	
3	Achieving consensus on an algorithm for the treatment of rheumatoid arthritis with methotrexate. <i>Arthritis and Rheumatism</i> , 1990 , 3, 53-57		
2	Rheumatoid Vasculitis392-402		

Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. *Interactive Journal of Medical Research*, **2022**, 11, e27273

2.1